COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (ARMY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02353143
Recruitment Status : Unknown
Verified October 2018 by Menarini Group.
Recruitment status was:  Recruiting
First Posted : February 2, 2015
Last Update Posted : January 29, 2019
Information provided by (Responsible Party):
Menarini Group

Brief Summary:
The purpose of this study is to assess the safety of MEN1112, given as intravenous infusion, in patients with relapsed or refractory AML. Pharmacokinetics, clinical activity and potential immunogenicity of MEN1112 will be evaluated as well.

Condition or disease Intervention/treatment Phase
Recurrent Adult Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse Drug: MEN1112 Phase 1

Detailed Description:

This trial is designed as an open label, non randomised, dose escalation and cohort expansion, first administration to human study to be conducted in approximately 20 European sites. The study is aiming to identify the Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), to assess the pharmacokinetics and to determine the clinical activity and potential immunogenicity of MEN1112, administered as IV infusion given once every week in a 21 days cycle in patients with relapsed/refractory acute myeloid leukemia (AML).

Approximately 50 male and female ≥ 18 years-old patients, with a documented diagnosis of relapsed or refractory AML (not M3 FAB subtype), will be treated in the study, which consists of two steps.

Step 1 is the dose escalation phase according to a 3+3 patients cohort design.Incremental mg/Kg doses will be tested given at day 1, 8 and 15 of a 21-day cycle. Briefly, MEN1112 doses are to be administered to 3 patients; if no DLT is observed in a cohort of 3 DLT evaluable patients at a given dose level, the next cohort of 3 new patients will be treated with the next higher dose. In case of DLT occurrence by one of the three patients at any dose, the cohort will be expanded to 6 DLT evaluable patients at the same dose level. If two or more patients at a given dose level exhibit DLT, the dose escalation phase will be concluded as the MTD will be identified as one dose level below the one at which ≥ 2 DLT out of 6 treated patients occur.

Step 2 is the cohort expansion phase which will include patients treated at the MTD or the maximum dose level judged to be tolerable.

In each study Step, patients will be given two induction cycles of MEN1112 followed by a three weeks End of Induction period. Patients will then undergo to 4 post-induction/maintenance visits every 28 days (maintenance administration is allowed in patients who achieve a clinical benefit based on Investigator's judgement) and to an End of Study Visit. Along the study period, adverse events, changes in hematology/serum biochemistry parameters and bone marrow treatment response will represent the major clinical findings to be monitored on regular basis. The individual experimental clinical phase will last up to 6 months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration) encompassing 40 planned visits at site, including Screening, Induction, End of Induction, Post-induction/Maintenance and the End of Study visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.
Actual Study Start Date : December 2014
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : May 2020

Arm Intervention/treatment
Experimental: MEN1112
Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
Drug: MEN1112
Intravenous infusion of MEN1112 pro/Kg body weight dose on days 1, 8, 15 of a 21-day cycle. Two induction cycles followed by a 3 week End of induction period. Post-induction/Maintenance Visits every 4 weeks with or without maintenance treatment administration, whilst clinical benefit is maintained as per Investigator's judgement. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).

Primary Outcome Measures :
  1. Dose limiting toxicity (DLT) [ Time Frame: over 3 weeks after the first dose ]

    DLT is defined as an adverse event occurring within the first induction cycle, judged to be related to MEN1112 and meeting any of the following criteria:

    • Grade 3 non- haematological toxicity lasting more than 7 days.
    • Grade ≥ 4 non- haematological toxicity

  2. Maximum tolerated dose (MTD) [ Time Frame: over 3 weeks after the first dose ]
    MTD is defined as one dose level below the Maximum Administered Dose (i.e. one dose level below the one at which ≥ 2 DLTs out of 6 treated patients occur).

Secondary Outcome Measures :
  1. Treatment Emergent Signs and Symptoms (TESSs) [ Time Frame: 6 months ]
    Incidence, severity, seriousness and treatment-causality of Treatment Emergent Signs and Symptoms (TESSs)

  2. MEN1112 Pharmacokinetic (PK) parameter AUC0-∞ [ Time Frame: Estimated maximum time frame: 4 weeks ]
    AUC0-∞ is the area under the serum concentration-time curve from time zero extrapolated to infinite time.

  3. MEN1112 PK parameter Cmax [ Time Frame: Estimated maximum time frame: 4 weeks ]
    Cmax is the maximum serum drug concentration

  4. MEN1112 PK parameter t1/2 [ Time Frame: Estimated maximum time frame: 4 weeks ]
    t1/2 is the drug elimination half-life

  5. Complete remission (CR) rate [ Time Frame: 6 months ]
    CR rate at any time point, where CR is defined as: bone marrow blasts <5%, absence of extramedullary disease, absolute neutrophil count >1 x 109/L and platelet count > 100 x 109/L

  6. Best response rate [ Time Frame: 6 months ]
    best observed response at any time point between CR, CRi [where CRi is defined as: all criteria for CR except residual thrombocytopenia (platelets <100 x 109/L) and/or neutropenia (absolute neutrophil count <1 x 109/L)] and partial remission [(PR): all haematological criteria for CR with bone marrow blasts 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%].

  7. Overall survival [ Time Frame: 6 months ]
    number of days between the first study drug administration and death from any cause

Other Outcome Measures:
  1. Immunogenicity of MEN1112 [ Time Frame: 64 days ]
    Incidence of anti-MEN1112 auto-antibodies

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients aged ≥ 18 years.
  • Documented definitive diagnosis of AML (according to WHO criteria, 2008) that is relapsed/refractory to standard treatment, for which no standard therapy is available or the patient refuses standard therapy.
  • WBC count ≤ 10 x 109/L at Visit 1 (Day 1); hydroxyurea is allowed to lower WBC count.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at Visit 1 (Day 1).
  • Life expectancy of at least 2 months.
  • Adequate renal and hepatic laboratory assessments: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤3.0 × ULN, unless considered due to leukemic organ involvement, Total Bilirubin ≤2.0 × ULN, Serum creatinine ≤2.0 × ULN.
  • Able to give written informed consent before any study related procedure

Exclusion Criteria:

  • Acute promyelocytic leukaemia (French-American-British M3 classification).
  • Active central nervous system involvement.
  • Haematopoietic stem cell transplantation (HSCT) performed within 3 months prior to Screening Visit.
  • Active infection requiring intravenous antibiotics.
  • Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety or interfere with the patient's ability to comply with the study activities.
  • Anti-tumour therapy within 14 days of study Visit 1 (Day 1, excluding hydroxyurea).
  • Prior participation in an investigational study (procedure or device) within 21 days of study Visit 1 (Day 1).
  • Radiotherapy within 28 days prior to study Visit 1 (Day 1) or scheduled along the study conduct.
  • Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
  • Other active malignancies. History of malignancy in the last 12 months (except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast or non-melanoma skin cancer).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02353143

Layout table for location contacts
Contact: Angela Capriati, MD, Corporate Director +39 055 5680 ext 9990
Contact: Simone Baldini, Clinical Research Physician +39 055 5680 ext 9740

Layout table for location information
ZNA Stuivenberg Recruiting
Antwerp, Belgium, 2060
Bruxelles, Belgium, 1200
Liège, Belgium, 4000
Yvoir, Belgium, 5530
Active, not recruiting
Lille, France, 59037
Active, not recruiting
Marseille, France, 13273
Active, not recruiting
Nantes, France, 44093
Active, not recruiting
Toulouse, France, 31059
Active, not recruiting
Villejuif, France, 94805
Dresden, Germany
Essen, Germany, 45147
Frankfurt, Germany, 60590
Munich, Germany, 81377
Active, not recruiting
Bologna, Italy, 40126
Active, not recruiting
Brescia, Italy, 25123
Milano, Italy, 20132
Active, not recruiting
Rome, Italy, 00133
Active, not recruiting
Torino, Italy, 10126
Badalona, Spain, 08916
Barcelona, Spain, 08035
Valencia, Spain, 46026
Sponsors and Collaborators
Menarini Group
Layout table for investigator information
Study Chair: Adriano Venditti, Professor, MD Hematology Department, "Tor Vergata" University Viale Oxford, 81 00133 Rome, Italy
Layout table for additonal information
Responsible Party: Menarini Group Identifier: NCT02353143    
Other Study ID Numbers: ARMY-1
2014-002433-59 ( EudraCT Number )
First Posted: February 2, 2015    Key Record Dates
Last Update Posted: January 29, 2019
Last Verified: October 2018
Keywords provided by Menarini Group:
Acute Myeloid Leukemia
Monoclonal antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type